TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04192929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band imaging
Description: Blue light is used during withdrawal phase instead of the regular white light to highlight surface changes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Indigo carmine will be sprayed during withdrawal phase of colonoscopy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High definition white light endoscopy
Description: High definition equipment will be used to perform colonoscopy
Study: NCT06580561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise coaching
Description: This is a 6-session personalized exercise coaching program (delivered over 8 weeks).~All participants will complete six 30-minute scheduled online or phone sessions with a health coach as part of a manualized personalized exercise program (once per week for the first four sessions and then once every two weeks for the remaining two sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise coaching
Description: This is a 6-session personalized exercise coaching program (delivered over 8 weeks).~All participants will complete six 30-minute scheduled online or phone sessions with a health coach as part of a manualized personalized exercise program (once per week for the first four sessions and then once every two weeks for the remaining two sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for Insomnia
Description: This is a 6-week course of automated, digitally delivered cognitive behavioral therapy for insomnia delivered by the online program Sleepio. The weekly sessions will last approximately 15-20 minutes.~Session content comprises evidence-based cognitive and behavioral techniques including Stimulus Control Therapy and Sleep Restriction Therapy, sleep hygiene education, and relaxation exercises.
Study: NCT06293352

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: All-cement articulating spacer
Description: Two-stage intervention

Intervention type: DEVICE
Group type: OTHER
Intervention: All-cement articulating spacer
Description: Two-stage intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durable, real-component articulating spacer
Description: Single stage intervention

Intervention type: DEVICE
Group type: OTHER
Intervention: Durable, real-component articulating spacer
Description: Single stage intervention

Intervention type: DEVICE
Group type: OTHER
Intervention: Rigid Spacer
Description: Observation intervention
Study: NCT06563583

Intervention type: OTHER
Intervention: Group 1 will include patients aged 18-40 years
Description: Group 1 will include patients aged 18-40 years.

Intervention type: OTHER
Intervention: Group 2 will include patients aged 40-64 years
Description: Group 2 will include patients aged 40-64 years, and finally.

Intervention type: OTHER
Intervention: Group 3 will include patients aged 65-85 years
Description: Group 3 will include patients aged 65-85 years.
Study: NCT05006573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Benralizumab
Description: Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Study: NCT04381013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emergency Ventilator Splitter
Description: Device to enable oxygen delivery to two patients independently from a single ventilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emergency Ventilator Splitter
Description: Device to enable oxygen delivery to two patients independently from a single ventilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emergency Ventilator Splitter
Description: Device to enable oxygen delivery to two patients independently from a single ventilator.
Study: NCT05035628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise training
Description: Participants will follow a 2-month exercise training program, thrice-weekly trainings. The training sessions will start with a 5-min warmup, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with respiratory exercises and cool down period (10 min). Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test.~A certified kinesiologist will supervise trainings. Heart rate, oxygen saturation and rating of perceived exertion (Borg Scale, 6-20) will be measured during training sessions.
Study: NCT06110910

Intervention type: DRUG
Intervention: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)
Description: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.

Intervention type: DRUG
Intervention: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)
Description: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.

Intervention type: DRUG
Intervention: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)
Description: Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
Study: NCT04482062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards EVOQUE System
Description: Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards EVOQUE System
Description: Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards EVOQUE System
Description: Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Optimal Medical Therapy
Study: NCT05665881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: vasopressor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: vasopressor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: vasopressor
Study: NCT06381791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: 150mg of Epidiolex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: 150mg of Placebo oral solution
Study: NCT04685031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Description: after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Description: after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Topical
Description: after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Topical
Description: after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the Angio catheter and the site was dressed with sterile gauze. In three time periods of 24, 48 and 72 hours from the time of venipuncture.
Study: NCT05736510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural sound
Description: When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the experimental group, the allocated file is binaural sound with 40Hz beat. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: When the pneumoperitoneum ends, the anesthesiologist puts headphones on the patient and plays the allocated file. In the control group, the allocated file is silent. Thereafter, the target of PSI is to be between 40 and 50. If the Psi increases above 50, increase the propofol concentration by 0.5 mg/mL and record it. Train of four counts keep between 1 to 3 (moderate block). When the operation is ended, stop anesthetics administration, and, we reverse neuromuscular blocking using sugammadex (2mg/ kg). When the anesthesiologist starts waking the patient up, call the patient's name (unify into OOO, open your eyes.). The anesthesiologist lightly tap the patient's shoulder and avoid excessive sound or stimulation.
Study: NCT05268107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Patients will be treated with dupilumab for 4 months (standard FDA-approved dosing of 600 mg subcutaneously at baseline/week 0, followed by 300 mg every 2 weeks).~Skin biopsies will be assessed at baseline (lesional and non-lesional), week 2 (lesional), and week 16 (lesional). In addition, blood will be obtained at baseline and week 16.
Study: NCT04832776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: one group plus cetuximab
Study: NCT04949399

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Injection
Study: NCT04832776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: one group plus bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI
Description: FOLFOXIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: FOLFOXIRI
Study: NCT06556004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRIMELVAX
Description: The safety of this immunotherapeutic compound will be tested in patients with advanced melanoma and will secondarily evaluate the induced immune response.
Study: NCT05091372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab Mafodotin~Belantamab mafodotin dose levels:~Dose level -2 = 1.4 mg/kg IV every 12 weeks Dose level -1 = 1.9 mg/kg IV every 12 weeks Dose level 0 = 1.9 mg/kg IV every 8 weeks~Cycles 1 - 6:~All patients will start at dose level 0.~Cycles 7 and onwards\*:~Patients previously on dose level 0 (1.9 mg/kg IV every 8 weeks) will change to dose level -1 (1.9 mg/kg IV every 12 weeks) Patients previously on dose level -1 (1.9 mg/kg IV every 12 weeks) will continue at the same dose level.~Patients previously on dose level -2 (1.4 mg/kg IV every 12 weeks) will continue at the same dose level.~\*Reduction to a lower dose level is allowed in case of development of adverse effects or poor tolerance as determined by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide dose levels:~Dose level 0 (starting dose): Lenalidomide 10 mg/day PO continuously. Dose level -1: Lenalidomide 10 mg/day PO. One week off after every three weeks of treatment.~Dose level -2: Lenalidomide 5 mg/day PO. One week off after every three weeks of treatment.
Study: NCT06654700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine (CHO Cell)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine (CHO Cell)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine (CHO Cell)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
Study: NCT06647485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PF-only PVI
Description: It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only PF energy for ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid PVI
Description: It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing both PF and RF energy for ablation. Specifically, PF energy is used for the posterior segments and RF energy for the anterior segments of the pulmonary veins

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF-only PVI
Description: It consists in performing a point-by-point PVI using the Dual Energy THERMOCOOL SMARTTOUCH™ SF (DE STSF) ablation catheter with the TRUPULSE™ generator, employing only RF energy for ablation
Study: NCT06593054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: Ceftibuten dihydrate, formulated in capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avibactam prodrug
Description: Avibactam prodrug, formulated in capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTB-AVP in Tablet
Description: ceftibuten and avibactam prodrug, in Tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTB-AVP in Tablet
Description: ceftibuten and avibactam prodrug, in Tablet formulation
Study: NCT06649851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulating Factor (G-CSF)
Description: Subcutaneously injected study drug; standard target dose of 5-7 µg/kg/d.

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy + Temozolomide
Description: Standard of care chemoradiation is radiation therapy + Temozolomide (TMZ). Chemoradiation (chemo-RT) includes an initial 6-week cycle, followed by a 4-week break, and up to 6 additional cycles of TMZ.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy + Temozolomide
Description: Standard of care chemoradiation is radiation therapy + Temozolomide (TMZ). Chemoradiation (chemo-RT) includes an initial 6-week cycle, followed by a 4-week break, and up to 6 additional cycles of TMZ.
Study: NCT06658522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Participants will receive open label subcutaneous sotatercept (starting dose, 0.3 mg per kilogram of body weight; target dose, 0.7 mg per kilogram) for 24 weeks
Study: NCT06070597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclepertin
Description: Iclepertin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclepertin Placebo
Description: Placebo to Iclepertin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iclepertin Placebo
Description: Placebo to Iclepertin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin
Study: NCT05909241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA1202
Description: BA1202 will be administered intravenously (IV) once every 3 weeks (Q3W) until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the duration of administration was no more than 2 years.~Part A: Patients will receive one of the following dosages of BA1202: 0.016mg, 0.08mg, 0.4mg, 1.6mg, 6.4mg, 19mg, 38mg, 56mg.~Part B: Based on the data of part A, one or two dose levels will be discussed for further evaluation in part B.
Study: NCT06070597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo Moxifloxacin
Study: NCT05674643

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound Baseline Scans
Description: The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound Baseline Scans
Description: The patient's abdomen will be scanned using the ultrasound device by an expert scanner and novice scanner for baseline assessment of the antral CSA and gastric volume using Perlas US qualitative grading assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Acetaminophen Absorption Test (AAT)
Description: Prior to starting the AAT, a baseline plasma acetaminophen level (250 microliters) will be obtained from the intravenous catheter. The subject will then be given 12.5 mg/kg or max 650mg of single batch 32mg/mL acetaminophen followed by 6oz of water PO. Up to 3 additional small volume blood samples will be drawn for acetaminophen levels.~These additional blood samples (250 microliters each) will be obtained to measure acetaminophen plasma levels at the following goal intervals after acetaminophen administration.T1:10-20 mins, T2:35-45 mins, T3: 60mins. At the time of each lab draw gastric ultrasound will be assessed by the expert scanner to correlate gastric ultrasound with the acetaminophen absorption test as a gold-standard of gastric emptying.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound Serial Scans
Description: Cohort 1 will have multiple scans as part of assessing gastric emptying. These sequential scans after the baseline assessment will be done in line with the Acetaminophen Absorption Test timeline (T1:10-20 mins, T2:35-45 mins, T3: 60mins) and will be performed by an expert scanner only.
Study: NCT06610526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin by oral administration
Study: NCT06611644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients in this group will receive an Erector Spinae Plane (ESP) block in addition to standard postoperative care. The ESP block will be performed under ultrasound guidance. A needle will be advanced in-plane or out-of-plane, targeting the lateral aspect of the T6 transverse process. Local anesthetic (20 to 30 ml) will be injected into the fascial plane between the erector spinae muscle and the transverse process. This block is intended to provide postoperative analgesia by blocking the transmission of pain through the thoracic spinal nerves.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPSIPB blcok
Description: Patients in this group will receive a Serratus Posterior Superior Intercostal Plane (SPSIP) block along with standard postoperative care. The SPSIP block will be performed under ultrasound guidance, where the needle is advanced between the second and third ribs towards the medial aspect of the scapula. Local anesthetic 20 to 30 ml) will be injected into the fascial plane between the serratus posterior superior muscle and the intercostal muscles after confirming needle placement with hydrodissection using 1-2 ml of saline. This block is intended to provide broad analgesia across the upper thoracic dermatomes, from C3 to T7, to control postoperative pain.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients in the control group will receive standard postoperative pain management without any regional block intervention. This will include the administration of systemic analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs). Opioid analgesics will be administered as needed based on the patient's pain level. Pain management will be conducted according to the standard protocol followed for breast surgery patients.
Study: NCT06611761

Intervention type: PROCEDURE
Intervention: Shoulder arthroscopy
Description: Shoulder arthroscopy in procedures that cause intense postoperative pain

Intervention type: PROCEDURE
Intervention: Shoulder arthroscopy
Description: Shoulder arthroscopy in procedures that cause intense postoperative pain
Study: NCT06606613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraurethral injection
Description: Procedure: Intraurethral injection~Patients are positioned in the lithotomy position during the procedure. General and/or local anesthesia is administered depending on the investigator\&amp;amp;#39;s preference. An applicator developed for intraurethral injection will be used. This device comprises a holder that is placed into and fixates the urethra (i.e., it distends the urethral circumference, thus smoothing out the longitudinal folds), allowing the use of four syringes to inject cross-linked hyaluronic acid/dextranomer at approximately the 2, 4, 8, and 10 o'clock positions.~Drug: Cross-linked hyaluronic acid/dextranomer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mid-urethral sling
Description: Procedure: Starting with the dorsal lithotomy position, a foley catheter is inserted to the urethra. Starting with 1-1.5 cm below the urethral meatus, a 1.5-2 cm vertical incision is made. Following the dissection of anterior vaginal mucosa, pubocervical fascia should be dissected sharply .~Dissection is continued laterally to the ischiopubic ramus. Starting downwards from the tendinous insertion of the adductor longus muscle at the level of clitoris, a 1cm incision is made close to the bone. The needle is placed in to the incision and passed medially through the obturator membrane. It has to be considered that the needle is passed very close to the bone in order not to damage the obturator vessel-nerve bundle. With the guidance of the opposite hand's index finger in the vaginal incision the tip of the needle has to be palpated afterwards passing with a 45-degree angle rotation. The next manoeuvre is passing the tip of the needle beside the urethra through the vaginal incision .
Study: NCT06613750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Gliclazide
Description: Participants in this arm will receive sitagliptin phosphate 100 mg once daily combined with gliclazide sustained-release tablets 30-120 mg once daily for 12 weeks